Bovie Medical Corporation Announces Clearance to Market Its BOSS Soft Tissue Coagulation Device

Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received clearance from the Food and Drug Administration (FDA) to market its proprietary BOSS™ bipolar sintered steel coagulation device. The BOSS™ is the latest device based on Bovie’s saline enhanced sintered steel technology.

The BOSS™ delivers RF energy simultaneously with saline to perform coagulation of soft tissue and bone resulting in reduced blood loss while minimizing charring and sticking of tissue. Saline enhanced surgeries reduce operating time while improving post-operative outcomes leading to shortened recovery time.

BIOLASE Announces FDA 510(K) Clearance of iLase (TM) Personal Laser for Dental Market

Completely Self-Contained Laser for Full Range of Minimally Invasive Soft-Tissue, Hygiene Procedures

BIOLASE Technology, Inc. (NASDAQ:BLTI), the world's leading dental laser company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its iLase™ diode laser, the world's first personal laser for dentists and hygienists for performing a full-range of minimally invasive soft-tissue and hygiene procedures.

The iLase is the first completely self-contained, hand-held dental laser that includes the laser, user interface, battery power, and controls in a single, integrated handpiece with no foot pedals or cords attached.

EDAP Receives Japanese Approval for Sonolith I-Sys

Enters Largest Global Lithotripsy Market

EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the Japanese Administration has granted marketing approval of its newly designed, high-end Sonolith I-Sys lithotripsy device.

The lithotripsy market in Japan ranks number one worldwide in both total lithotripsy sales volume and installed base. Physicians in Japan have been historically quick to adopt new innovative, high-end devices. As the latest device to enter the Japanese market, the Sonolith I-Sys is an easy to use and effective tool that delivers benefits to both patients and physicians. With unique, integrated and robotized features, Sonolith I-Sys fully addresses the Japanese lithotripsy market demands for new high-end technologies.

NuVasive Announces Insurance Provider Policy Reversal to Cover XLIF(R)

NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Aetna changed its spinal surgery policy to include coverage for the eXtreme Lateral Interbody Fusion, or XLIF procedure, published on February 26, 2010, a reversal from its previous policy that labeled XLIF as experimental and investigational.

The updated policy states that lateral interbody fusion is considered an acceptable method of performing a medically necessary anterior interbody fusion, in accordance with the North American Spine Society (NASS) recommendation letter dated January 5, 2010. NuVasive will update its reimbursement website accordingly.